How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,166 results for

Alopecia Areata

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. HrQoL in hair loss affected patients with Alopecia Areata, Androgenetic Alopecia and Telogen Effluvium: The role of personality traits and psychosocial anxiety. (Abstract)

HrQoL in hair loss affected patients with Alopecia Areata, Androgenetic Alopecia and Telogen Effluvium: The role of personality traits and psychosocial anxiety. Illness impact on HrQoL has been widely studied in hair loss-affected patients, yet no study has addressed whether individual differences modulate HrQoL in patients with alopecia areata (AA), androgenetic alopecia (AGA) and telogen effluvium (TE).To identify the personality dimensions most predictive of the impact of disease on HrQoL.A (...) . A significant Gender × Group interaction was also found for trait anxiety, social phobia and social anxiety: consistently, AGA females reported higher scores than AGA males in all three measures. Finally, discriminant analysis evidenced that anxiety-related traits can contribute to reliably predict hair loss impact on HrQoL, regardless of illness severity and alopecia type.We recommend that gender and individual differences in anxiety-related dimensions be considered as key factors in gaining a deeper

2018 Journal of the European Academy of Dermatology and Venereology

2. Establishing and Prioritising Research Questions for the Prevention, Diagnosis and Treatment of Hair Loss (excluding Alopecia Areata): The Hair Loss Priority Setting Partnership. Full Text available with Trip Pro

Establishing and Prioritising Research Questions for the Prevention, Diagnosis and Treatment of Hair Loss (excluding Alopecia Areata): The Hair Loss Priority Setting Partnership. Hair and scalp problems are common. Unfortunately, many uncertainties exist around the most effective management and treatment strategies for these disorders.To identify uncertainties in hair-loss management, prevention, diagnosis and treatment that are important to both people with hair loss and healthcare (...) professionals.A Hair Loss Priority Setting Partnership was established between patients, their carers and relatives, and healthcare professionals to identify the most important uncertainties in hair loss. The methodology of the James Lind Alliance was followed to ensure a balanced, inclusive and transparent process.In total, 2747 treatment uncertainties were submitted by 912 participants; following exclusions 884 uncertainties relating to hair loss (excluding alopecia areata) were analysed. Questions were

2017 British Journal of Dermatology

3. Alopecia areata

Alopecia areata Evidence Maps - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4

2018 Trip Evidence Maps

5. Alopecia areata

Alopecia areata Alopecia areata - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Alopecia areata Last reviewed: February 2019 Last updated: November 2017 Summary Autoimmune disease that targets the hair follicle. Characterised by sudden onset of patchy hair loss. Diagnosis is clinical. Characteristic physical findings are exclamation mark hairs (short, broken hairs) and a positive pull test. A scalp biopsy shows (...) perifollicular inflammation. Topical or intralesional corticosteroids are appropriate for patients with limited hair loss. Skin atrophy can be a temporary side effect. Definition Alopecia areata (AA) is an autoimmune disease that affects almost 2% of the population in the US. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70:628-633. http://www.ncbi.nlm.nih.gov/pubmed/7791384?tool=bestpractice.com Inflammatory cells

2017 BMJ Best Practice

6. The Microbial Origin of Baldness: Sabouraud's Researches into the Relations Between Seborrhœa, Alopecia Areata, and Baldness Full Text available with Trip Pro

The Microbial Origin of Baldness: Sabouraud's Researches into the Relations Between Seborrhœa, Alopecia Areata, and Baldness 20756940 2011 03 29 2011 03 29 0007-1447 1 1895 1897 Apr 24 British medical journal Br Med J The Microbial Origin of Baldness: Sabouraud's Researches into the Relations Between Seborrhoea, Alopecia Areata, and Baldness. 1028-30 Wickham L L eng Journal Article England Br Med J 0372673 0007-1447 2010 8 27 6 0 1897 4 24 0 0 1897 4 24 0 1 ppublish 20756940 PMC2433497

1897 British medical journal

7. Alopecia Areata Progression Index, a Scoring System for Evaluating Overall Hair Loss Activity in Alopecia Areata Patients with Pigmented Hair: A Development and Reliability Assessment. Full Text available with Trip Pro

Alopecia Areata Progression Index, a Scoring System for Evaluating Overall Hair Loss Activity in Alopecia Areata Patients with Pigmented Hair: A Development and Reliability Assessment. No scoring systems to evaluate overall hair loss activity in alopecia areata (AA) have been established.We sought to develop a measurement tool (Alopecia Areata Progression Index, AAPI) for the evaluation of overall hair loss activity in AA patients with pigmented hair.The scalp surface area was divided into 4 (...) quadrants. In each quadrant, hair loss activity was scored on the basis of the percentage of alopecic area, clinical findings associated with hair loss. The AAPI was measured in 17 patients with different severities of AA.Interobserver and intraobserver reliabilities were assessed by 4 investigators. A significant correlation of the total AAPI was found among the 4 investigators. In addition, intraobserver reliability was excellent, and interobserver reliability was statistically reliable.The AAPI seems

2016 Dermatology

8. ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

the last dose of study medication. Diffuse alopecia areata or a history of an atypical pattern of AA. Concomitant hair loss disorder (by history or physical exam) such as androgenetic alopecia (AGA) or scarring alopecia. Active skin disease on the scalp or a history of skin disease on the scalp that in the opinion of the investigator would interfere with study assessments of efficacy or safety. Active scalp trauma or other condition affecting the scalp that, in the investigator's opinion, may affect (...) Vehicle - oral administration Drug: Placebos Vehicle - oral administration Other Name: Placebo Comparator: vehicle Outcome Measures Go to Primary Outcome Measures : The primary efficacy variable will be the mean change from Baseline in the Severity of Alopecia Tool (SALT) score at end of study. [ Time Frame: 24 weeks ] The percentage hair growth will be calculated as the mean change from baseline compared to end-of-treatment. The SALT score is a global severity score that captures percentage hair loss

2018 Clinical Trials

9. Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. (Abstract)

Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. 29679494 2018 10 27 1468-3083 32 11 2018 Nov Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Risk of sun-induced skin cancers in patients with alopecia areata, alopecia totalis and alopecia universalis. e409-e411 10.1111/jdv.15002 Conic R R Z RRZ Department of Dermatology, Cleveland Clinic Foundation, Cleveland, OH, USA. Department

2018 Journal of the European Academy of Dermatology and Venereology

10. ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

in subjects with AA, AU or AT following 24 weeks of treatment with ATI-501 Oral Suspension or Placebo Suspension. To assess the ability of ATI-502 Topical Solution to maintain or improve hair regrowth in subjects previously treated with ATI-501 Oral Suspension or Placebo Suspension. Condition or disease Intervention/treatment Phase Alopecia Areata Alopecia Universalis Alopecia Totalis Drug: ATI 502 0.46% Topical Solution Phase 2 Detailed Description: This Phase 2, multicenter, open-label study (...) : Proportion of subjects achieving a SALT 50 or SALT 75 at Week 24 (n study ATI-501-AUAT-201) and maintaining that response at week 24 in ATI-502-AA-203 study. Mean Relative Percent Change from Baseline SALT score [ Time Frame: week 24 ] Mean Relative Percent Change from Baseline (from the current study ATI-502-AA-203) in Severity of Alopecia Tool (SALT). SALT score is on a percent scale where 0% is no hair loss and 100 % is total hair loss. A lower SALT score is a better outcome. A higher relative percent

2018 Clinical Trials

11. Alopecia areata multiplex following autologous dermal micro-graft injection for treatment of androgenetic alopecia. (Abstract)

Alopecia areata multiplex following autologous dermal micro-graft injection for treatment of androgenetic alopecia. Alopecia areata (AA) is an autoimmune disease of the hair follicle (HF). Human anagen HFs are protected by immune privilege, defined in part as the absence of MHC class I antigen expression. AA is postulated to occur when the immune-privileged state of the HF is compromised 1 ; however, the immunopathogenesis, including autoantigens, of AA remain incompletely defined. Recently (...) , through genome-wide association studies, gene expression analysis, and a C3H/HeJ mouse model of AA, the cytotoxic subset of CD8+NKG2D+ T cells was revealed to play a major role in AA development 2-4 . In contrast to AA, androgenetic alopecia (AGA) is believed to be caused by androgens on the hair cycles. Among other autologous transplantation procedures, autologous dermal micro-grafts have recently been used to treat AGA 5,6 . Herein, we report a case of AA that developed following an autologous

2019 Journal of the European Academy of Dermatology and Venereology

12. Congenital Absence of Hair and Mammary Glands with Atrophic Condition of the Skin and its Appendages, in a Boy whose Mother had been almost wholly Bald from Alopecia Areata from the age of Six Full Text available with Trip Pro

Congenital Absence of Hair and Mammary Glands with Atrophic Condition of the Skin and its Appendages, in a Boy whose Mother had been almost wholly Bald from Alopecia Areata from the age of Six 20896687 2011 03 29 2011 03 29 0959-5287 69 1886 Medico-chirurgical transactions Med Chir Trans Congenital Absence of Hair and Mammary Glands with Atrophic Condition of the Skin and its Appendages, in a Boy whose Mother had been almost wholly Bald from Alopecia Areata from the age of Six. 473-7 Hutchinson

1886 Medico-chirurgical transactions

13. CASE OF COMPLETE BALDNESS FROM ALOPECIA AREATA: (In Progress of Recovery under Treatment.) Full Text available with Trip Pro

CASE OF COMPLETE BALDNESS FROM ALOPECIA AREATA: (In Progress of Recovery under Treatment.) 20760179 2011 03 29 2011 03 29 0007-1447 1 2154 1902 Apr 12 British medical journal Br Med J CASE OF COMPLETE BALDNESS FROM ALOPECIA AREATA: (In Progress of Recovery under Treatment.). 884-5 Squire B B eng Journal Article England Br Med J 0372673 0007-1447 2010 8 27 6 0 1902 4 12 0 0 1902 4 12 0 1 ppublish 20760179 PMC2512091

1902 British medical journal

14. Scalp bacterial shift in Alopecia areata. Full Text available with Trip Pro

Scalp bacterial shift in Alopecia areata. The role of microbial dysbiosis in scalp disease has been recently hypothesized. However, little information is available with regards to the association between microbial population on the scalp and hair diseases related to hair growth. Here we investigated bacterial communities in healthy and Alopecia areata (AA) subjects. The analysis of bacterial distribution at the genus level highlighted an increase of Propionibacterium in AA subjects alongside (...) composition of the different area surrounded hair follicle from the epidermis to hypodermis, highlighting differences between normal and AA affected the scalp. Our results highlight, for the first time, the presence of a microbial shift on the scalp of patients suffering from AA and gives the basis for a larger and more complete study of microbial population involvement in hair disorders.

2019 PLoS ONE

15. Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer Full Text available with Trip Pro

subsequently developed scalp alopecia, with histopathological features of both androgenetic alopecia and alopecia areata; the hair loss did not resolve after completion of her chemotherapy. Significant clinical improvement was observed with topical minoxidil therapy. PubMed was searched for the following terms: alopecia, breast, cancer, chemotherapy, endocrine, hair, loss, minoxidil, permanent, and taxane. The papers containing these terms and their references were reviewed. Temporary hair loss (...) Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer Taxane chemotherapy and adjuvant endocrine therapy are commonly used in breast cancer patients following surgery. We describe a 59-year-old woman with a triple-positive invasive right breast cancer that was treated with surgery, radiation, chemotherapy, and adjuvant hormonal therapy. She

2018 Cureus

16. The value of dermoscopy in diagnosing eyebrow loss in patients alopecia areata and frontal fibrosing alopecia. Full Text available with Trip Pro

areata (62% and 58%, respectively), frontal fibrosing alopecia (60% and 84%, respectively) and healthy controls (100% and 100%, respectively).Trichoscopy of the eyebrow area is useful in diagnosing patients with isolated eyebrow loss. The most characteristic trichoscopic features of eyebrow loss in alopecia areata include exclamation mark hairs, tapered hairs, broken hairs and black dots. Frontal fibrosing alopecia of the eyebrows is characterized by the presence of dystrophic hairs, white areas (...) The value of dermoscopy in diagnosing eyebrow loss in patients alopecia areata and frontal fibrosing alopecia. Alopecia areata and frontal fibrosing alopecia are common causes of eyebrow loss (madarosis).Assessment of trichoscopic markers of eyebrow loss in alopecia areata and frontal fibrosing alopecia.The analysis included 50 patients with scalp alopecia areata with madarosis, 50 patients with scalp frontal fibrosing alopecia with madarosis and 50 healthy controls. In every case, trichoscopy

2018 Journal of the European Academy of Dermatology and Venereology

17. Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29 Full Text available with Trip Pro

Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29 29853767 2018 11 14 1013-9087 30 3 2018 Jun Annals of dermatology Ann Dermatol Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. 388-391 10.5021/ad.2018.30.3.388 Jun Myungsoo M Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. Keum Dong In DI Department (...) of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. Lee Solam S Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. Kim Beom Jun BJ Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. Lee Won-Soo WS https://orcid.org/0000-0001-7198-1334 Department of Dermatology and Institute of Hair

2018 Annals of dermatology

18. Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata. (Abstract)

Utility of Horizontal Sections of Scalp Biopsies in Differentiating between Androgenetic Alopecia and Alopecia Areata. Androgenetic alopecia (AGA) and alopecia areata (AA) are common causes of alopecia which can sometimes be difficult to differentiate clinically. Horizontal sections of scalp biopsies are used to study non-cicatricial alopecias due to the ability to perform both quantitative and morphometric analysis of hair follicles on them.It was a prospective, cross-sectional study conducted (...) to assess the utility of horizontal sections to differentiate between the alopecias. Fifty-two cases were included: 20 cases of male AGA, 11 of female AGA and 21 cases of AA. After clinical examination and dermoscopy, a skin biopsy was taken and subjected to transverse sectioning. Histopathological assessment was done by two dermatopathologists blinded to clinical details.Among the quantitative parameters, terminal:vellus hair ratio (3.08 in AGA and 1.83 in AA, p = 0.0091) and anagen:non-anagen hair

2018 Dermatology

19. Alopecia areata

Alopecia areata Alopecia areata - NICE CKS Share Alopecia areata: Summary Alopecia areata is a chronic, inflammatory condition affecting the hair follicles which leads to sudden onset of non-scarring alopecia (hair loss where the hair follicles are generally preserved). Any hair-bearing skin can be involved, but it most commonly affects the scalp or beard and, less frequently, the eyebrows and eyelashes. Total loss of scalp hair (alopecia totalis) or scalp and body hair (alopecia universalis (...) ) is rare. Nail changes are seen in 10–15% of people. Alopecia areata occurs when hairs are prematurely converted from the growth (anagen) to the loss (telogen) phase, but the exact cause is unknown. Alopecia areata is a relatively common condition and is estimated to affect 15 in 10,000 people in the UK. It can present at any age, and males and females are affected equally. The prognosis of alopecia areata is unpredictable. Spontaneous remission within one year may be seen in up to 80% of people

2018 NICE Clinical Knowledge Summaries

20. Distinguishing diffuse alopecia areata (AA) from pattern hair loss (PHL) using CD3<sup>+</sup> T cells. (Abstract)

Distinguishing diffuse alopecia areata (AA) from pattern hair loss (PHL) using CD3+ T cells. Distinguishing between diffuse subacute alopecia areata (AA), in which the peribulbar infiltrate is absent, and pattern hair loss is challenging, particularly in cases that lack marked follicular miniaturization and a marked catagen/telogen shift.We sought to distinguish diffuse AA from pattern hair loss using CD3(+) T lymphocytes.A total of 28 cases of subacute AA and 31 cases of pattern (...) hair loss were selected and a 4-mm punch biopsy was performed. All the specimens were processed using the "HoVert" (horizontal and vertical) technique. In all cases, hematoxylin-eosin and immunohistochemical stains for CD3, CD4, CD8, and CD20 were performed.The presence of CD3(+) lymphocytes within empty follicular fibrous tracts (stela), even without a concomitant peribulbar infiltrate, is a reliable histopathological clue in supporting a diagnosis of AA (sensitivity 0.964, specificity 1, P ≤ .001

2016 Journal of American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>